Effects of Metronidazole, Tetracycline, and Bismuth-Metronidazole-Tetracycline Triple Therapy in the Helicobacter pylori SS1 Mouse Model after 1 Day of Dosing: Development of an H. pylori Lead Selection Model

AUTOR(ES)

Sizemore, Christine F.

FONTE

American Society for Microbiology

RESUMO

We evaluated the effect of optimized doses and dosing schedules of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline (BMT) triple therapy with only 1 day of dosing on Helicobacter pylori SS1 titers in a mouse model. A reduction of bacterial titers was observable with 22.5 and 112.5 mg of metronidazole per kg of body weight (as well as BMT) given twice daily and four times daily (QID). Two hundred milligrams of tetracycline per kilogram, given QID, resulted in only a slight reduction of H. pylori titers in the stomach. We argue that optimization of doses based on antimicrobial drug levels in the animal and shortened (1 or 2 days) drug administration can be used to facilitate early evaluation of putative anti-H. pylori drug candidates in lieu of using human doses and extended schedules (7 to 14 days), as can be deduced from the results seen with these antimicrobial agents.

Documentos Relacionados

• Mouse-Colonizing Helicobacter pylori SS1 Is Unusually Susceptible to Metronidazole Due to Two Complementary Reductase Activities
• In Vivo Behavior of a Helicobacter pylori SS1 nixA Mutant with Reduced Urease Activity
• Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains.
• In Vitro Activities of a New Ketolide, ABT-773, Alone and in Combination with Amoxicillin, Metronidazole, or Tetracycline against Helicobacter pylori
• Insulin-like growth factor-I in Helicobacter pylori gastritis and response to eradication using bismuth based triple therapy.